Research Article| Volume 59, ISSUE 2, P236-242, August 2013

The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values

Published:March 25, 2013DOI:

      Background & Aims

      Progressive fibrosis is a major cause of morbidity and mortality in chronic liver disease. To replace liver biopsy for disease staging, multiple serum markers are under evaluation with multiparametric panels yielding the most promising results. The Enhanced Liver Fibrosis (ELF) score is an ECM marker set consisting of tissue inhibitor of metalloproteinases 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic acid (HA) showing good correlations with fibrosis stages in chronic liver disease.


      The ELF score was measured in 400 healthy controls and 79 chronic hepatitis C patients using an ADVIA Centaur automated system. The ELF score was calculated using the published algorithm combining TIMP-1, PIIINP and HA values. Patients’ fibrosis stage was defined histologically. ROC analyses were performed to study marker validity. Reference values and influence factors for the ELF score were validated.


      ELF score reference values ranged from 6.7 to 9.8 and were significantly higher for men vs. women (7.0–9.9 vs. 6.6–9.3, respectively). Afternoon values were slightly higher than morning values (6.7–9.9 vs. 6.6–9.5, respectively). Age was a notable influence factor. We identified three cut-off values: 7.7 for a high sensitivity exclusion of fibrosis, 9.8 for a high specificity identification of fibrosis (sensitivity 69%, specificity 98% for moderate fibrosis), and 11.3 to discriminate cirrhosis (sensitivity 83%, specificity 97%). ELF score validity was superior to the results of the single tests.


      The ELF score can predict moderate fibrosis and cirrhosis. However, influence factors such as gender and age need to be taken into account.


      ELF (enhanced liver fibrosis), ECM (extracellular matrix), TIMP-1 (tissue inhibitor of metalloproteinases 1), PIIINP (amino-terminal propeptide of type III procollagen), HA (hyaluronic acid), HSC (hepatic stellate cells), CHC (chronic hepatitis C), HCV (hepatitis C virus), ALT (alanine aminotransferase), AST (aspartate aminotransferase), AP (alkaline phosphatase), γGT (gamma-glutamyltransferase), CI (confidence interval), Kcal (kilocalories), ROC (receiver operating characteristics), AUC (area under the curve.)


      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Poynard T.
        • Ratziu V.
        • Benmanov Y.
        • Di Martino V.
        • Bedossa P.
        • Opolon P.
        Fibrosis in patients with chronic hepatitis C: detection and significance.
        Semin Liver Dis. 2000; 20: 47-55
        • Friedman S.L.
        Hepatic fibrosis.
        in: Schiff E.R. Sorrell M.F. Maddrey W.C. Schiff’s diseases of the liver. Lippincott, Williams & Wilkins, PS, USA2003: 409-427
        • Hernandez-Gea V.
        • Friedman S.L.
        Pathogenesis of liver fibrosis.
        Annu Rev Pathol. 2011; 6: 425-456
        • Ramadori G.
        • Saile B.
        Mesenchymal cells in the liver – one cell type or two?.
        Liver. 2002; 22: 283-294
        • Ishak K.
        • Baptista A.
        • Bianchi L.
        • et al.
        Histological grading and staging of chronic hepatitis.
        J Hepatol. 1995; 22: 696-699
        • Anonymous
        Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Co-operative Study group.
        Hepatology. 1994; 20: 15-20
        • Knodell R.G.
        • Ishak K.G.
        • Black W.C.
        • et al.
        Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.
        Hepatology. 1981; 1: 431-435
        • Scheuer P.J.
        Classification of chronic viral hepatitis: a need for reassessment.
        J Hepatol. 1991; 13: 372-374
        • Gebo K.A.
        • Herlong T.F.
        • Torbenson M.S.
        • et al.
        Role of liver biopsy on management of chronic hepatitis C: a systematic review.
        Hepatology. 2002; 36: S161-S172
        • Lichtinghagen R.
        • Bahr M.J.
        Noninvasive diagnosis of fibrosis in chronic liver disease.
        Expert Rev Mol Diagn. 2004; 4: 89-100
        • Giannini E.
        • Testa R.
        Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple.
        Hepatology. 2003; 38: 1312-1313
        • Forns X.
        • Ampurdanes S.
        • Llovet J.M.
        • et al.
        Identification of chronic hepatitis C without hepatic fibrosis by a simple predictive model.
        Hepatology. 2002; 36: 986-992
        • Wai C.T.
        • Greenson J.K.
        • Fontana R.J.
        • Kalbfleisch J.D.
        • Marrero J.A.
        • Conjeevaram H.S.
        • et al.
        A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.
        Hepatology. 2003; 38: 518-526
        • Imbert-Bismut F.
        • Ratziu V.
        • Pieroni L.
        • Charlotte F.
        • Benhamou Y.
        • Poynard T.
        Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.
        Lancet. 2001; 357: 1069-1075
        • Rosenberg W.M.
        • Voelker M.
        • Thiel R.
        • Becka M.
        • Burt A.
        • Schuppan D.
        • et al.
        Serum markers detect the presence of liver fibrosis: a cohort study.
        Gastroenterology. 2004; 127: 1704-1713
        • Hoffmann G.
        Forschungsbericht: IT-Werkzeuge zur Auswertung großer labordiagnostischer Datensätze.
        42. DGKL Mitteilungen, 2011 (p. 124–130. Software-Download:
        • Horn P.S.
        • Pesce A.J.
        Reference intervals. A user’s guide.
        AACC Press, Washington (DC)2005
        • Harris E.K.
        • Boyd J.C.
        On diving reference data into subgroups to produce separate reference ranges.
        Clin Chem. 1990; 36: 265-270
        • Nguyen D.
        • Talwalkar J.A.
        Noninvasive assessment of liver fibrosis.
        Hepatology. 2011; 53: 2107-2110
        • Baranova A.
        • Lal P.
        • Birerdinc A.
        • Younossi Z.M.
        Non-invasive markers for hepatic fibrosis.
        BMC Gastroenterol. 2011; 11: 91
        • Castera L.
        Noninvasive methods to assess liver disease in patients with hepatitis B or C.
        Gastroenterology. 2012; 142: 1293-1302
        • Guha I.N.
        • Parkes J.
        • Roderick P.
        • Chattopadhyay D.
        • Cross R.
        • Harris S.
        • et al.
        Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers.
        Hepatology. 2008; 47: 455-460
        • Mayo M.J.
        • Parkes J.
        • Adams-Huet B.
        • Combes B.
        • Mills A.S.
        • Markin R.S.
        • et al.
        Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.
        Hepatology. 2008; 48: 1549-1557
        • Nobili V.
        • Parkes J.
        • Bottazzo G.
        • Marcellini M.
        • Cross R.
        • Newman D.
        • et al.
        Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.
        Gastroenterology. 2009; 136: 160-167
        • Parkes J.
        • Roderick P.
        • Harris S.
        • Day C.
        • Mutimer D.
        • Collier J.
        • et al.
        Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.
        Gut. 2010; 59: 1245-1251
        • Martinez S.M.
        • Fernández-Varo G.
        • González P.
        • Sampson E.
        • Bruguera M.
        • Navasa M.
        • et al.
        Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
        Aliment Pharmacol Ther. 2011; 33: 138-148
        • Trépo E.
        • Potthoff A.
        • Pradat P.
        • Bakshi R.
        • Young B.
        • Lagier R.
        • et al.
        Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease.
        J Hepatol. 2011; 55: 38-44
        • Crespo G.
        • Fernández-Varo G.
        • Mariño Z.
        • Casals G.
        • Miquel R.
        • Martínez S.M.
        • et al.
        ARFI, FibroScan®, ELF, and their combinations in the assessment of liver fibrosis: a prospective study.
        J Hepatol. 2012; 57: 281-287
        • Wahl K.
        • Rosenberg W.
        • Vaske B.
        • Manns M.P.
        • Schulze-Osthoff K.
        • Bahr M.J.
        • et al.
        Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.
        PLoS One. 2012; 7: e51906